Publication
Adjuvant oxaliplatin with S-1 (SOX) versus S-1 for stage II-III gastric cancer (CAPITAL): A randomized, open-label, phase 3 trial.
Run-Cong Nie, Shi Chen, Jin Wan, Xiao-Wei Sun, Wei-Qin Hong, Hong-Bo Wei, Wei Wang, Wen-Bin Zhang, Yan Zhao, Wei-Bin Zhang, Jing-Song Chen, Zu-Guang Wu, Cong Mai, Chun-Zai Feng, Shu-Qiang Yuan, Wei Wang, Hai-Bo Qiu, Yao Liang, Yuan-Xiang Guan, Yong-Ming Chen, Wen-Wu Liu, Chao Ding, Jun-Sheng Peng, Ying-Bo Chen, Zhi-Wei Zhou, Yuan-Fang Li
- Source
- PubMed
- Retrieved
- Sep 15, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260915-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: Adjuvant chemotherapy following D2 gastrectomy constitutes the standard-of-care for resectable gastric or gastroesophageal junction (GEJ) carcinoma. The CAPITAL trial is a multicenter, randomized, phase 3 study, aiming to assess the efficacy and safety of adjuvant oxaliplatin plus S-1…
Read on PubMedLinked entities
Linked entities (2)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT01795027registry_reference1.00
Candidate 1
- cancerMalignant Gastric Neoplasmdictionary0.60
Registered trialsNCT01795027
Curated evidence
Evidence citing this paper (0)
Data not yet available